{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:24Z","timestamp":1793367144471,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejso.2026.112044","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:15:55Z","timestamp":1785424555000},"page":"112044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The myth of eradicating peritoneal surface malignancies: How ultramicroscopic disease undermines the potential benefits of hyperthermic intraperitoneal chemotherapy"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3947-1064","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Corral-San Miguel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Gonz\u00e1lez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Tom\u00e1s-Loba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9547-5508","authenticated-orcid":false,"given":"Juan","family":"Rodr\u00edguez-Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gil-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0078-5920","authenticated-orcid":false,"given":"Vicente","family":"Olivares-Ripoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2295-5161","authenticated-orcid":false,"given":"Jer\u00f3nimo","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2831-9975","authenticated-orcid":false,"given":"Alberto Rafael","family":"Guijarro-Campillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Antonio","family":"Cascales-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.112044_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112044_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ejso.2026.112044_bib3","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2026.112044_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: rationale and technique","volume":"2","author":"Gonz\u00e1lez-Moreno","year":"2010","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib6","doi-asserted-by":"crossref","first-page":"9731","DOI":"10.1245\/s10434-025-18196-7","article-title":"Assessing the annual risk of recurrence following complete CRS-HIPEC for diffuse malignant peritoneal mesothelioma","volume":"32","author":"P\u00e9ron","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib7","article-title":"Recurrence patterns following CRS-HIPEC in patients with colorectal peritoneal metastases","volume":"51","author":"Tbm","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-019-0991-5","article-title":"Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance","volume":"18","author":"Mashouri","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejso.2026.112044_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejso.2026.112044_bib10","doi-asserted-by":"crossref","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejso.2026.112044_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2019.10.034","article-title":"Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review","volume":"127","author":"Auer","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2026.112044_bib12","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.7974","article-title":"Direct and indirect anticancer effects of hyperthermic intraperitoneal chemotherapy on peritoneal malignancies","volume":"45","author":"Zhang","year":"2021","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejso.2026.112044_bib13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","article-title":"Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence","volume":"7","author":"Ceelen","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.soc.2018.02.003","article-title":"Pharmacokinetics and tissue transport of intraperitoneal chemotherapy","volume":"27","author":"Lagast","year":"2018","journal-title":"Surg Oncol Clin"},{"key":"10.1016\/j.ejso.2026.112044_bib16","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib15","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"Eight-year follow-up of randomized trial: CRS-HIPEC versus systemic chemotherapy","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib23","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and HIPEC improves survival in gastric cancer peritoneal carcinomatosis","volume":"18","author":"Yang","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib93","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus HIPEC versus surveillance (PROPHYLOCHIP","volume":"21","author":"Go\u00e9r\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib94","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (COLOPEC","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2026.112044_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.22.02644","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced Colon cancer (COLOPEC): 5-year results of a randomized multicenter trial","volume":"42","author":"Zwanenburg","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus HIPEC versus CRS alone for colorectal peritoneal metastases (PRODIGE 7","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib95","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib96","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejso.2026.112044_bib97","doi-asserted-by":"crossref","first-page":"11491","DOI":"10.1007\/s00432-023-05019-z","article-title":"Hyperthermic intraperitoneal chemotherapy plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study","volume":"149","author":"Yu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","article-title":"Efficacy and safety of intraoperative HIPEC for locally advanced colon cancer (HIPECT4","volume":"158","author":"Arjona-S\u00e1nchez","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejso.2026.112044_bib98","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib99","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial","volume":"42","author":"Rau","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib100","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.24.00686","article-title":"Hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a randomized trial on survival evaluation (HORSE; MITO-18","volume":"43","author":"Fagotti","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Wj","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2026.112044_bib22","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without HIPEC for stage III ovarian cancer (OVHIPEC-2","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2026.112044_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-183","article-title":"GASTRICHIP: D2 resection and HIPEC in locally advanced gastric carcinoma","volume":"14","author":"Glehen","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.112044_bib25","article-title":"PERISCOPE II trial protocol","volume":"19","author":"Koemans","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.112044_bib26","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/codi.15368","article-title":"Prospective correlation of radiological, surgical and pathological PCI","volume":"22","author":"Bhatt","year":"2020","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.ejso.2026.112044_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1245\/s10434-015-4627-8","article-title":"Linear relationship of PCI and survival in colorectal peritoneal metastases","volume":"23","author":"Faron","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejso.2017.11.003","article-title":"Prognostic value of peritoneal cancer index in advanced ovarian cancer","volume":"44","author":"Llueca","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib29","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1245\/s10434-024-15629-7","article-title":"Assessment of intraoperative scoring systems for predicting cytoreduction outcome","volume":"31","author":"Tozzi","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib30","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.1245\/s10434-021-10193-w","article-title":"HIPEC methodology and regimens: the need for an expert consensus","volume":"28","author":"Bhatt","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133114","article-title":"Hyperthermic intraperitoneal chemotherapy: a critical review","volume":"13","author":"Ceelen","year":"2021","journal-title":"Cancers (Basel"},{"key":"10.1016\/j.ejso.2026.112044_bib32","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1245\/s10434-024-15646-6","article-title":"The 2022 PSOGI International Consensus on HIPEC regimens for peritoneal malignancies: pseudomyxoma peritonei","volume":"31","author":"Kusamura","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib33","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1002\/ijc.32762","article-title":"The cancer exosomes: clinical implications, applications and challenges","volume":"146","author":"Tang","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejso.2026.112044_bib34","article-title":"Exosomal miRNAs: key regulators of the tumor microenvironment and cancer stem cells","volume":"26","author":"Wang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejso.2026.112044_bib35","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.cmet.2021.09.002","article-title":"Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche","volume":"33","author":"Morrissey","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.ejso.2026.112044_bib36","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2017.0065","article-title":"Cisplatin induces the release of extracellular vesicles from ovarian cancer cells","volume":"373","author":"Samuel","year":"2018","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.ejso.2026.112044_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040307","article-title":"Review of the isolation, characterization, biological function, and therapeutic approaches of exosomes","volume":"8","author":"Gurunathan","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejso.2026.112044_bib38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.18632\/oncotarget.27531","article-title":"Exosome-mediated miR-155 delivery confers cisplatin chemoresistance","volume":"11","author":"Kirave","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejso.2026.112044_bib39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14728222.2020.1785431","article-title":"The role of microRNA in cisplatin resistance or sensitivity","volume":"24","author":"Wang","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ejso.2026.112044_bib40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tox.2013.02.014","article-title":"miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN","volume":"306","author":"Yang","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.ejso.2026.112044_bib41","article-title":"Exosome-mediated chemoresistance in cancers","volume":"15","author":"Liu","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejso.2026.112044_bib42","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1158\/1541-7786.MCR-17-0784","article-title":"Exosomes induce fibroblast differentiation into cancer-associated fibroblasts","volume":"16","author":"C","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ejso.2026.112044_bib43","article-title":"Exosomes released from PD-L1+ tumor-associated macrophages promote peritoneal metastasis of ovarian cancer","volume":"36","author":"Ma","year":"2023","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.ejso.2026.112044_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1679934","article-title":"Cancer-derived exosomes: mediators of immune crosstalk and emerging targets for immunotherapy","volume":"16","author":"Mahamed","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejso.2026.112044_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/02656736.2017.1312563","article-title":"Tumour tissue transport after intraperitoneal anticancer drug delivery","volume":"33","author":"Carlier","year":"2017","journal-title":"Int J Hyperther"},{"key":"10.1016\/j.ejso.2026.112044_bib46","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","article-title":"Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer","volume":"7","author":"Rm","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/02656730701455318","article-title":"Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy","volume":"23","author":"Sugarbaker","year":"2007","journal-title":"Int J Hyperther"},{"key":"10.1016\/j.ejso.2026.112044_bib49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug administration","volume":"89","author":"Dedrick","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2026.112044_bib50","article-title":"Prolonged HIPEC exposure and survival benefit in ovarian cancer","volume":"14","author":"Acs","year":"2022","journal-title":"Cancers (Basel"},{"key":"10.1016\/j.ejso.2026.112044_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710078","article-title":"Molecular and cellular mechanisms of HIPEC in epithelial ovarian cancer","volume":"23","author":"Lim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejso.2026.112044_bib52","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ygyno.2015.06.012","article-title":"HIPEC in ovarian cancer: new era or end of the pipeline?","volume":"139","author":"Cascales-Campos","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib53","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1245\/s10434-006-9305-4","article-title":"Short-term paclitaxel exposure with or without hyperthermia induces long-term growth inhibition","volume":"14","author":"Michalakis","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib54","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/ijc.34220","article-title":"HIPEC efficacy according to HRD\/BRCA genomic profile","volume":"151","author":"Bhatt","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejso.2026.112044_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2020.08.013","article-title":"New approaches for targeting platinum-resistant ovarian cancer","volume":"77","author":"McMullen","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejso.2026.112044_bib56","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejso.2026.112044_bib57","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","article-title":"Peritoneal carcinomatosis","volume":"19","author":"Coccolini","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejso.2026.112044_bib58","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1245\/s10434-007-9648-5","article-title":"Safety and efficacy of HIPEC with high-dose oxaliplatin","volume":"15","author":"Ceelen","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib59","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei treated by CRS and HIPEC","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib60","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1245\/s10434-014-4111-x","article-title":"Institutional learning curve of CRS and HIPEC for peritoneal malignancies","volume":"22","author":"Polanco","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jso.25939","article-title":"CRS and HIPEC: technical considerations and the learning curve","volume":"122","author":"Vining","year":"2020","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib62","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1245\/s10434-023-13932-3","article-title":"PSOGI International consensus on HIPEC regimens for epithelial ovarian cancer","volume":"30","author":"Bhatt","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib63","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1245\/s10434-022-11949-8","article-title":"Socioeconomic barriers to CRS-HIPEC for appendiceal cancer","volume":"29","author":"Rieser","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","article-title":"Exosomes","volume":"88","author":"Pegtel","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.ejso.2026.112044_bib65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13578-019-0282-2","article-title":"Exosomes: biogenesis, biologic function and clinical potential","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci"},{"key":"10.1016\/j.ejso.2026.112044_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130472","article-title":"Exosomal miRNAs from peritoneal lavage fluid as prognostic biomarkers in gastric cancer","volume":"10","author":"Tokuhisa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2026.112044_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA detects minimal residual disease and predicts recurrence in colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejso.2026.112044_bib68","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","article-title":"Preoperative circulating tumor DNA predicts progression-free survival in peritoneal carcinomatosis","volume":"25","author":"Baumgartner","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib69","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/cr.2014.44","article-title":"Double-stranded DNA in exosomes: a novel biomarker in cancer detection","volume":"24","author":"Thakur","year":"2014","journal-title":"Cell Res"},{"key":"10.1016\/j.ejso.2026.112044_bib70","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1704862114","article-title":"Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy","volume":"114","author":"Sansone","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejso.2026.112044_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1180","article-title":"Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences","volume":"2","author":"Balaj","year":"2011","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejso.2026.112044_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092921","article-title":"Circulating exosomal microRNAs as biomarkers of colon cancer","volume":"9","author":"Ogata-Kawata","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2026.112044_bib73","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02318-0","article-title":"Dynamic liquid biopsy components as predictive biomarkers in colorectal cancer","volume":"41","author":"Raza","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejso.2026.112044_bib74","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","article-title":"Circulating tumor DNA in stage III colorectal cancer","volume":"28","author":"Henriksen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2026.112044_bib75","article-title":"Circulating exosomal miRNAs as biomarkers in colorectal cancer","volume":"22","author":"Ads","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejso.2026.112044_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210230","article-title":"Circulating tumor DNA as minimal residual disease assessment and recurrence risk in colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Chidharla","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejso.2026.112044_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102595","article-title":"Strategies for improving detection of circulating tumor DNA using next-generation sequencing","volume":"119","author":"T\u00e9bar-Mart\u00ednez","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejso.2026.112044_bib78","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.7150\/thno.59644","article-title":"Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejso.2026.112044_bib79","article-title":"Genomics and epigenomics approaches for quantification of circulating tumor DNA in liquid biopsy","volume":"26","author":"E","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejso.2026.112044_bib80","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","article-title":"Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells","volume":"15","author":"Nakamura","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ejso.2026.112044_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.791418","article-title":"Ascites and serial plasma circulating tumor DNA for predicting the effectiveness of hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis","volume":"12","author":"Pu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejso.2026.112044_bib82","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/cancers17091461","article-title":"Liquid biopsy in peritoneal carcinomatosis from colorectal cancer: current evidence and future perspectives","volume":"17","author":"Martelli","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejso.2026.112044_bib83","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2026.112044_bib84","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejpb.2021.10.001","article-title":"High-pressure nebulization of hydrogels for intraperitoneal drug delivery","volume":"169","author":"Braet","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejso.2026.112044_bib85","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-019-0563-2","article-title":"Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer","volume":"18","author":"Liang","year":"2020","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.ejso.2026.112044_bib86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2024.07.017","article-title":"Intraperitoneal drug delivery systems for peritoneal carcinomatosis","volume":"373","author":"Perell\u00f3-Trias","year":"2024","journal-title":"J Contr Release"},{"key":"10.1016\/j.ejso.2026.112044_bib87","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.3892\/ol.2017.6324","article-title":"miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN","volume":"14","author":"Yu","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejso.2026.112044_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010526","article-title":"MicroRNA expression profile in cisplatin- and paclitaxel-resistant ovarian cancer cell lines","volume":"23","author":"Kazmierczak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejso.2026.112044_bib89","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4049\/jimmunol.1400703","article-title":"Dendritic cell\u2013derived exosomes as immunotherapies in the fight against cancer","volume":"193","author":"Pitt","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.ejso.2026.112044_bib90","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ymthe.2018.01.001","article-title":"Exosomes deliver anti-miR-214 to reverse cisplatin resistance in gastric cancer","volume":"26","author":"Wang","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejso.2026.112044_bib91","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/cbin.11671","article-title":"Exosomal miR-21-5p promotes glycolysis and inhibits chemosensitivity in ovarian cancer","volume":"45","author":"Zhuang","year":"2021","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.ejso.2026.112044_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010603","article-title":"Utilization of exosome-based therapies to augment anti-PD-1\/PD-L1 therapies","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:44:53Z","timestamp":1793364293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326006633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0748798326006633"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112044","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The myth of eradicating peritoneal surface malignancies: How ultramicroscopic disease undermines the potential benefits of hyperthermic intraperitoneal chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112044"}}